Baseline characteristics of the SB2 cohort and the historical originator infliximab (OI) cohort
| OI→SB2 (n=45) | Historical OI cohort (n=52) | P value | |
|---|---|---|---|
| Age, mean (SD) | 53.2 (2,1) | 50.25 (1.2) | 0.194 |
| Female (n, %) | 25 (55%) | 31 (59%) | 0.690 |
| Spondylarthropathy (n, %) | 28 (62%) | 33 (62%) | 0.901 |
| Type of SpA | |||
| Axial SpA (n, %) | 25 (89%) | 32 (97%) | 0.234 |
| Peripherical SpA including PsA (n, %) | 16 (35.5) | 22 (42.3%) | 0.821 |
| MRI lesions (n, %) | 17 (61%) | 20 (60%) | 0.811 |
| HLA B27+ (n, %) | 19 (68%) | 20 (61%) | 0.335 |
| Inflammatory bowel disease (n, %) | 7 (25%) | 8 (24%) | 0.947 |
| Uveitis (n, %) | 6 (21%) | 4 (12%) | 0.363 |
| Psoriasis (n, %) | 7 (25%) | 10 (30%) | 0.599 |
| Methotrexate Dose mg/week, mean (SD) | 6 (86%) 13 (1.9) | 7 (100) 12.8 (1.6) | 0.613 |
| BASDAI, mean (SD) | 27.7 (4.6) | 31.3 (4.9) | 0.554 |
| CRP, mg/l, mean, (SD) | 5 (1.9) | 5.5 (2.2) | 0.907 |
| PGS/100, mean (SD) | 32.1 (5.4) | 38.7 (5.5) | 0.907 |
| Psoriatic arthritis DAS28, n, mean (SD) | 5, 1.9 (0.2) | 7, 2.3 (0.5) | 1 |
| Rheumatoid arthritis (n, %) | 17 (38%) | 20 (38%) | 0.946 |
| ACPA+ (n, %) | 16 (94%) | 19 (95%) | 0.909 |
| Erosive disease (n, %) | 13 (76%) | 14 (70%) | 0.669 |
| Corticosteroids (n, %) | 6 (35.2%) | 8 (40%) | 0.776 |
| Dose corticosteroids | 4.9 (0.8) | 5.5 (0.5) | 0.429 |
| Methotrexate Dose mg/week, mean (SD) | 10 (100%) 13.7 (1.4) | 14 (100%) 15.2 (1.1) | 0.437 |
| DAS28 CRP, mean (SD) | 2.5 (0.3) | 2.8 (0.26) | 0.511 |
| CRP, mg/l, mean (SD) | 3.8 (1.7) | 2.1 (0.7) | 0.560 |
| PGS/100, mean (SD) | 36 (7.4) | 49.5 (6) | 0.276 |
| Swollen joint count, mean (SD) | 0.2 (0.1) | 1.2 (0.5) | 0.916 |
| Fibromyalgia (n, %) | 3 (6.6%) | 3 (5.8%) | 0.876 |
| Anxiety-depression (n, %) | 6 (13.3%) | 8 (15.4%) | 0.748 |
| Characteristics of the treatment | |||
| No. of BD lines before IFX, mean (SD) | 0.4 (0.1) | 0.4 (0.1) | 0.791 |
| Mean time under OI (month), mean (SD) | 113.5 (9.3) | 94.8 (9.4) | 0.066 |
| Number of previous injections | 64.8 (5.4) | 54.1 (4.7) | 0.104 |
| Dose (mg/kg), mean (SD) | 4.5 (0.1) | 4.6 (0.1) | 0.512 |
| Infusion rhythm, mean (SD) | 7.5 (0.2) | 7.3 (0.2) | 0.559 |
ACPA, Anti-citrullinated protein antibody; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BD, biologic drug; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; IFX, Infliximab; OI, Originator infliximab Remicade; PGS, Patient global score; SpA, Spondylarthropathy.